Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk - Reuters

Chronological Source Flow
Back

AI Fusion Summary

Eli Lilly’s new oral GLP‑1 weight‑loss pill, orforglipron branded Foundayo, received FDA approval, becoming the second daily pill in this class after Novo Nordisk’s Wegovy. It offers a non‑injectable option for obesity treatment.
Community Comments
Loading updates...
0